Antimicrobial peptides (AMPs) are prospective therapeutic options for treating multiple-strain infections. However, clinical and commercial development of AMPs has some limitations due to their limited stability, low bioavailability, and potential hemotoxicity. The purpose of this study was to develop new polymeric carriers as highly controlled release devices for amphibian peptides citropin 1.1 (CIT) and temporin A (TEM). The release rate of the active pharmaceutical ingredients (APIs) was strongly dependent on the API characteristics and the matrix microstructure. In the current work, we investigated the effect of the polymer microstructure on in vitro release kinetics of AMPs. Non-contact laser profilometry, scanning electron microscopy (SEM), and differential scanning calorimetry (DSC) were used to determine the structural changes during matrix degradation. Moreover, geno- and cytotoxicity of the synthesized new carriers were evaluated. The in vitro release study of AMPs from the obtained non-toxic matrices shows that peptides were released with near-zero-order kinetics. The peptide “burst release” effect was not observed. New devices have reached the therapeutic concentration of AMPs within 24 h and maintained it for 28 days. Hence, our results suggest that these polymeric devices could be potentially used as therapeutic options for the treatment of local infections.

Keywords: antimicrobial peptides; biodegradable polymers; biocompatible polymers; drug delivery systems; controlled release; citropin; temporin; ionic liquids
a diverse class of naturally occurring biologically active molecules with a broad spectrum of activity. They possess activity against viruses, both Gram-positive and Gram-negative bacteria (with endotoxin-neutralizing activity), fungi, and protozoa. Moreover, AMPs display anti-inflammatory, immunomodulatory, antitumor, angiogenic, and wound healing properties [4–6].

However, from the therapeutic point of view, clinical and commercial development of AMPs as low-molecular-weight active pharmaceutical ingredients (APIs) still has some limitations. AMPs have limited stability, low bioavailability, and potential hemotoxicity. In order to overcome the above-mentioned issues, peptides could be loaded into polymeric drug delivery systems (DDSs). Non-toxic polymeric matrices with appropriate microstructure would be able to release APIs with optimal pharmacokinetics, improving the efficacy and toxicological safety of the therapy [7]. Novel DDSs, which are characterized by highly controlled drug release profiles, are currently being demanded by both the pharmaceutical industry and medical practitioners.

Recent studies focused on the development of polymeric carriers for AMPs or short lipopeptides. The tested matrices were poly (lactic acid-co-castor oil) [8], poly (ester-anhydride) [8], poly(ε-caprolactone) (PCL) [9], copolymer of ε-caprolactone and trimethylene carbonate [9] and polyphosphoesters [10]. New systems were reported to be effective against Enterococcus faecalis [8], Bacillus anthracis [9], Enterococcus hirae [9], Staphylococcus aureus [9,10], Escherichia coli [10] and Pseudomonas aeruginosa [10]. However, the previous studies did not take into account the determination of the kinetics and mechanisms of the peptide release from the new systems. Moreover, there are no studies based on released amount of peptides with reference to therapeutic index (TI). AMPs due to their high hydrophobicity are able to interact not only with bacterial cell membranes, but also with red blood cells, so they show hemolytic activity in certain concentrations. Therefore, it is very important to achieve a therapeutic concentration of peptides in the target tissues. The TI for AMPs defined by Chen et al. [11] is a ratio that compares the minimal hemolytic concentration (MHC) that induces erythrocyte lysis and the minimal inhibitory concentration (MIC) that inhibits the visible growth of the bacterium being investigated. Larger TI values indicate simultaneously greater antimicrobial specificity of the peptide molecule.

In this study, new polymeric matrices were synthesized by enzymatic ring opening polymerization (εROP) of ε-caprolactone (CL) in order to obtain non-toxic devices for highly controlled and prolonged release of amphibian AMPs: citropin 1.1 (CIT) and temporin A (TEMP).

CIT, a 16–amino acid (GLFDVIKKVASVIGGL-NH₂) cationic peptide (+2 at pH 7) is produced by the tree frog Litoria citropa [12]. It has a high content of hydrophobic residues (56%) in its molecule and an average molecular mass of 1397 Da. CIT is one of the simplest amphibian peptides with a broad spectrum of biological activity reported to date. The solution structure of CIT is an alpha helix with well-defined hydrophobic/hydrophilic regions. CIT has shown antimicrobial activity toward Gram-positive bacteria (Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, Rhodococcus equi, Bacillus subtilis) with antibiofilm properties [13,14]. Moreover, it has antifungal and antitumor activity [15,16].

TEMP is a short, 13–amino acid peptide (FLPLIGRVLSGIL-NH₂) isolated from skin secretions of the European red frog Rana temporaria. It has a positive net charge (+2 at pH 7) and a higher content of hydrophobic residues (61%) than CIT. Average molecular mass of TEMP is 1615 Da. It has broad antimicrobial activity against both Gram-positive and Gram-negative bacteria [17]. We chose ionic liquids (ILs) as an alternative to the volatile organic solvents during poly(ε-caprolactone) PCL synthesis [18]. ILs are commonly known as solvents that enhance enzyme stability and activity. Moreover, they affect the microstructure of the polymers [19]. The amount of drug released was mainly dependent on the kind of polyester, its number average molecular weight (Mₙ), dispersity (Mₘ/Mₙ), or microstructure. However, our main intention was to check how the kinetics of peptide release might depend on the microstructural characteristics of the polyester matrices.
2. Materials and Methods

2.1. Materials

CL (≥97%; Aldrich, Poznan, Poland) was dried and distilled over CaH₂ at reduced pressure before use. Immobilized lipase B from *Candida antarctica* (CALB) (catalog #L4777) was purchased from Sigma, Poland. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide ([bmim][NTf₂] ≥98%; Aldrich, Poznan, Poland) and 1-butyl-3-methylimidazolium hexafluorophosphate ([bmim][PF₆] ≥ 98%, Merck, Poland) were used as received. CIT (≥95%) and TEMP (≥95%) (Lipopharm.pl, Poland) were used as received. Dichloromethane (DCM), toluene, and methanol (Avantor, Gliwice, Poland) were used as received. Phosphate buffered saline (PBS) was purchased from Sigma (Poznan, Poland) and was also used as received. Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA).

2.2. Synthesis of Polymeric Matrices

In a typical experiment, the substrate (3.0 g of CL) was mixed with solvent (3.0 mL) under argon atmosphere, followed by the addition of 300 mg CALB, according to our previously described method [20]. Finally, the obtained PCL was precipitated in cold methanol, filtered, and dried under vacuum at room temperature for 4 days.

2.3. Spectroscopy Data of PCL

$^1$H-NMR (CDCl₃, δ, ppm): 4.07 [2H, t, –CH₂CH₂CH₂OC(O)–], 3.66 [2H, t, –CH₂OH], 2.32 [2H, t, –CH₂CH₂CH₂CH₂COO–], 1.67 [4H, m, –CH₂CH₂CH₂CH₂COO–], 1.39 [2H, m, –CH₂CH₂CH₂CH₂COO–]; $^{13}$C-NMR (CDCl₃, δ, ppm): 173.7 [–C(=O)O–], 64.3 [–CH₂CH₂CH₂CH₂OC(O)–], 62.7 [–CH₂OH], 34.3 [–CH₂CH₂CH₂CH₂COO–], 28.5 [–CH₂CH₂CH₂CH₂OC(O)–], 25.7 [–CH₂CH₂CH₂CH₂COO–], 24.7 [–CH₂CH₂CH₂CH₂COO–]; FT-IR (KBr, cm$^{-1}$): 3440 (νO-H), 2938 (νas CH₂), 2866 (νas CH₃), 1727 (νC=O), 1245 (νC-O).

2.4. Preparation of Poly(ε-Caprolactone) Devices of CIT and TEMP

The obtained PCL matrices were dissolved in DCM under argon atmosphere. Then, the CIT or TEMP was slowly added to the vigorously stirred PCL solution. The samples were dried in vacuo at room temperature until a constant weight was reached. The tablet disc (13 mm diameter, 1 mm thick) was obtained using a hydraulic press (Specac, London, UK) at 98 kN. The mean weight of the developed devices was about 200 mg, corresponding to approximately 5 mg of peptide.

2.5. Genotoxicity Assay of Polymeric Matrices

The *umu*-test was performed with *Salmonella typhimurium* TA1535/pSK1002 in 96-well microplates according to the ISO 13829 protocol with and without metabolic activation, as we described before [21].

2.6. Neutral Red Uptake (NRU) Assay of Polymeric Matrices

Cytotoxicity assays were performed on BALB/c 3T3, clone A31 mammalian fibroblasts (American Type Culture Collection) on the basis of the ISO 10993-5:2009 guideline: Biological evaluation of medical devices—Part 5: Tests for in vitro cytotoxicity. Cells were seeded into 96-well microplates (10⁴ cells·mL⁻¹) in DMEM culture medium (supplemented with 10% calf bovine serum, 100 IU/mL penicillin, and 0.1 mg·mL⁻¹ streptomycin) and incubated for 24 h (5% CO₂, 37 °C, >90% humidity). Subsequently wells were examined under a microscope, and culture medium was replaced with the tested extracts (prepared as for the *umu*-test) mixed with the treatment medium (1:1). All extracts were tested in twofold dilution series for 24 h (4 data points for each one). The next day, cells were washed with PBS and treated with the neutral red medium for 3 h and then with desorbing fixative (ethanol and acetic acid water solution). The amount of neutral red accumulated by cells was evaluated.
colorimetrically at 540 nm. PBS and SLS were used as negative and positive controls, respectively. The cell viability was calculated relative to the negative control.

2.7. Tests for In Vitro Cytotoxicity of Polymeric Matrices

For the cytotoxicity test, agar cells were seeded (1.5 \times 10^5 \text{ cells} \cdot \text{mL}^{-1}, \text{DMEM supplemented as for the NRU test}) into 6-well plates and maintained in culture for 24 h. The next day, each plate was examined under a microscope, and the culture medium was replaced with fresh DMEM with 1% agar. Round or square sterile samples (about 1 cm diameter/side length) of all tested materials were placed carefully on the solidified agar layer in each well. As negative and positive controls, polyethylene foil and latex were used, respectively. In each test one well seeded with cells was left with clear surface as a control of the cell culture. After 24 h, cells were examined under a microscope to determine the cytotoxic effect before and after carefully removing the specimens from the agar.

2.8. In Vitro Studies of Citropin 1.1 and Temporin A Release from Polymeric Devices

The polymeric devices were immersed in 0.1 M PBS (10 mL) at 37 °C and gently shaken. The sample solutions were withdrawn for analysis at selected time intervals and replaced with new buffer solution. The quantity of peptide was analyzed by high-performance liquid chromatography (HPLC). The samples were prepared in triplicate.

2.9. Measurements

The polymerization products were characterized by means of \(^1\)H and \(^{13}\)C NMR (Varian 300 MHz, Palo Alto, CA, USA) at room temperature, with CDCl\(_3\) as solvent. Fourier transform infrared (FT-IR) spectra were measured from KBr pellets (Perkin Elmer spectrometer, Perkin Elmer, Warsaw, Poland).

SEC traces were recorded using an Agilent 1100 Series isocratic pump, a degasser, an autosampler thermostatic box for columns, and a set of TSKgel columns (2 \times \text{PLGel 5 microns MIXED-C}) at 30 °C. A Wyatt Optilab rEX interferometric refractometer and a MALS DAWN EOS laser photometer (Wyatt Technology Corp., Santa Barbara, CA, USA) were used as detectors. Methylene chloride was used as the eluent, at a flow rate of 0.8 mL \cdot \text{min}^{-1}. \(M_n\) and \(M_w/M_n\) were calculated from the experimental traces using the Wyatt ASTRA v 4.90.07 program.

\(M_n\) and \(M_w/M_n\) of the obtained polyesters were determined by SEC/MALS with a system composed of an Agilent 1100 chromatograph series with an isocratic pump, an autosampler, a degasser, and a thermostatic box for columns. Refractive index (OPTILAB rex, Wyatt Technology Corporation, Santa Barbara, CA, USA) and MALS (DAWN EOS, Wyatt Technology Corporation, Santa Barbara, CA, USA) were applied as detectors and the TSKgel HXL columns were used in series for separations. DCM was used as eluent at a flow rate of 0.8 mL \cdot \text{min}^{-1}.

The matrix-assisted laser desorption/ionization mass spectrometry (MALDI-ToF-MS) experiments were performed on an Axima-Performance TOF spectrometer (Shimadzu Biotech, Manchester, UK), equipped with a nitrogen laser (337 nm) using a dithranol (1,8-dihydroxy-9(10H)-anthracenone) matrix.

Thermogravimetric analyses (TGA) were performed using TA Instruments Q50 (New Castle, DE, USA) at a heating rate of 10 °C \cdot \text{min}^{-1} under nitrogen flow (60 mL \cdot \text{min}^{-1}). Differential scanning calorimetry (DSC) measurements were performed using a TA Instruments DSC Q20 (New Castle, DE, USA) with aluminum pans at a heating rate of 10 °C \cdot \text{min}^{-1} under nitrogen flow (50 mL \cdot \text{min}^{-1}). The degree of crystallinity (\(X_c\)) was calculated from the peak enthalpies normalized to the actual weight fraction of polymer using Equation (1):

\[
X_c = \left[\frac{\Delta H_f (T_m)}{\Delta H_f (T_{0m})}\right] \times \left[\frac{\Delta H_f (T_{0m})}{\Delta H_f (T_{0m})}\right]^{-1}
\]

where \(\Delta H_f (T_m)\) is the enthalpy of fusion at the melting point and \(\Delta H_f (T_{0m})\) is the heat of fusion of 100% crystalline PCL (139.5 J \cdot \text{g}^{-1}).
Morphological assessment of the samples was carried out with a FEI Quanta 250 FEG scanning electron microscope (SEM) (FEI Inc., Eindhoven, The Netherlands).

Surfaces of tablet matrices were determined with the help of a Contact 3D surface profiler (Taylor Hobson TalySurf CCI Lite, Ametek, UK).

HPLC was performed using a Waters apparatus with the use of an Agilent ZORBAX column (1.8 um, SB-C18, 4.6 \times 50 \text{ mm}). The mobile phase consisted of water (0.1% formic acid) and acetonitril (0.1% formic acid) at a flow rate of 1 ml\cdot\text{min}^{-1}.

2.10. Mathematical Models for Peptide Release Studies

The release data points were subjected to zero-order and first-order kinetics and Higuchi and Korsmeyer–Peppas models \[22–24\].

Zero-order model:

\[
F = kt
\]

First-order model:

\[
\log F = \log F_0 - \frac{kt}{2.303}
\]

Korsmeyer–Peppas model:

\[
F = kt^n \quad (F < 0.6)
\]

where \(F\) is the fraction of peptide released up to time \((t)\), \(F_0\) is the initial concentration of peptide, \(k\) is the constant of the mathematical models, and \(n\) is the exponent of the Korsmeyer–Peppas model.

3. Results and Discussion

3.1. Characterization of PCL Matrices

The purpose of our work was to obtain nontoxic PCLs as devices for highly controlled release of CIT and TEMP. Biodegradable polyesters were synthesized using CALB as a biocatalyst. Lipase was used to avoid the difficulty of completely removing the residual of the conventional metal catalyst from the final product. This paper is a continuation of our earlier investigations \[20\]. The polymerization was carried out at 60 and 80 \(°\text{C}\) for 7 days in two ILs: \([\text{bmim}][\text{NTf}_2]\) and \([\text{bmim}][\text{PF}_6]\). Moreover, the process was performed without solvent to compare the effect of ILs on PCL characterization.

As is commonly known, many factors can influence the release rate of API from polymeric matrices. It is mainly dependent on the kind of polymer and its \(M_n, M_w/M_n\), and microstructure. However, our main intention was to check how peptide release kinetics could be dependent on the polymeric matrix microstructure, thus polyester matrices were synthesized and characterized (Table 1).

### Table 1. Characterization of poly(\(\varepsilon\)-caprolactone) (PCL) matrices synthesized in the presence of \textit{Candida antarctica} (CALB) in ionic liquids (ILs).

| No. | Solvent         | Temp. \[°C\] | \(M_n\) \[Da\] | \(M_w/M_n\) \[^b\] | Yield \([^c\]%\] | Conv. \[^c\]% | \(T_c\) \[^d\] \[°C\] | \(T_m\) \[^d\] \[°C\] | \(\Delta H_f\) \[^e\] \[J\cdotg^{-1}\] | \(X_c\) \[^e\]% | \(T_{deg}\) \[^e\] \[°C\] | MC \[^f\]% |
|-----|----------------|--------------|----------------|-----------------|----------------|--------|----------------|----------------|----------------|-------------|----------------|--------|
| PCL-1 | \[\text{bmim}][\text{NTf}_2]\ | 80 | 6100 | 1.8 | 78 | 95 | 34.7 | 53.1 | 70.4 | 50.5 | 405.4 | 35 |
| PCL-2 | \[\text{bmim}][\text{PF}_6]\ | 80 | 5700 | 1.5 | 87 | 92 | 28.5 | 50.6 | 78.4 | 56.3 | 410.3 | 19 |
| PCL-3 | \[\text{bmim}][\text{NTf}_2]\ | 60 | 3600 | 2.0 | 88 | 90 | 32.1 | 50.4 | 73.7 | 52.8 | 406.9 | 23 |
| PCL-4 | \[\text{bmim}][\text{PF}_6]\ | 60 | 2100 | 1.4 | 85 | 94 | 30.4 | 47.3 | 82.7 | 59.2 | 411.7 | 0 |
| PCL-5 | – | 80 | 1000 | 2.4 | 61 | 73 | 31.6 | 49.1 | 75.7 | 54.2 | 407.9 | 0 |
| PCL-6 | – | 60 | 2700 | 1.2 | 78 | 87 | 32.5 | 50.4 | 84.6 | 60.1 | 414.5 | 0 |

\[^a\] Determined by SEC using the correction coefficient \(M_n(\text{SEC}) = 0.56\cdot M_n(\text{SEC raw data})\); \[^b\] determined by SEC; \[^c\] determined by \(^1\text{H} \text{NMR} \[20\]; \[^d\] onset temperature; \[^e\] determined by MALDI-ToF-MS.

The chemical structure of the obtained homopolymers was confirmed by \(^{13}\text{C}, ^1\text{H} \text{NMR} \) (Figure 1) and IR studies (Experimental section).

The \(M_n\) of PCLs synthesized in ILs was determined by SEC and was in the range of 2100–6100 Da. The \(M_w/M_n\) indices were about 1.5 for homopolymers synthesized in \([\text{bmim}][\text{PF}_6]\) and about 1.9 for
homopolymers synthesized in [bmim][NTf₂]. The reaction yields ranged from 78 to 88%. The results obtained in bulk conditions confirm our earlier assumptions that ILs improve enzyme stability at higher temperatures and lead to obtaining polyesters with higher \( M_n \), lower \( M_w/M_n \), and a higher conversion.

The thermal properties of the synthesized matrices determined by the DSC method showed that PCLs synthesized in [bmim][NTf₂] were characterized by a lower degree of crystallinity \( (X_c) \) (50.5–52.8%) as compared to PCLs obtained in [bmim][PF₆] under the same experimental conditions (56.3–59.2%). The low \( X_c \) values for PCLs is related to the high content of amorphous domains of cyclic macromolecules in the polymer structure that are formed as side products during eROP \[25\]. The amorphous domains in the PCL chain are mobile and have less packing, while the linear chains in the crystalline domains are rigid and take up less space. As a result, macrocycles show greater exposure of ester bonds to water during hydrolysis, so they degrade faster \[26,27\]. The content of cyclic oligomers can be controlled by selecting the appropriate reaction conditions. Analysis of the PCL structure determined by MALDI-ToF-MS and DSC showed that the highest content of macrocycles (35%) and the highest proportion of the amorphous phase (about 49.5%) was noted for PCL-1 synthesized in [bmim][NTf₂] at 80 °C.

To evaluate the biocompatibility of the matrices, which is extremely important for medical devices like internal implants or urinary and venous catheters, we performed toxicity assays on the selected PCL samples synthesized in different ILs. For the first bioassay, the \( \text{umu} \) test was used to evaluate the genotoxic potential of the tested materials. The genotoxic potential of the sample is presented as the induction ratio (IR). Results with IR \( \geq 1.5 \) are considered genotoxic. Additionally, bacteria growth (G) is evaluated by a measurement of optical density to determine the toxicity of the tested samples.

All tested samples (Table 2) were not toxic for \textit{Salmonella typhimurium} TA1535 (G > 0.5). The IR rises as a result of different types of DNA damage that induces the \( \text{umuC} \) gene in the SOS system linked in this bacterial strain to the synthesis of \( \beta \)-galactosidase. The IR ratio of both samples did not differ from the results obtained for negative or solvent control, therefore none of the tested PCLs matrices exhibited genotoxic activity (IR < 1.5). Similar negative results were evaluated with and without metabolic activation which disclaims the activity of tested samples as a procarcinogens in this bioassay.
Table 2. The umu-test results for the highest concentrations of tested extracts (0.67 mg·mL\(^{-1}\)).

| Sample            | −S9 \(^a\) | IR ± SD     | +S9 \(^b\) | IR ± SD     |
|-------------------|------------|-------------|------------|-------------|
| PCL-1             | 0.90 ± 0.08| 0.97 ± 0.14 | 0.87 ± 0.03| 0.94 ± 0.07 |
| PCL-2             | 0.92 ± 0.05| 1.02 ± 0.09 | 0.88 ± 0.01| 0.90 ± 0.08 |
| Solvent control   | 1.01 ± 0.09| 0.94 ± 0.15 | 0.88 ± 0.01| 1.03 ± 0.06 |
| Negative control  | 1.00 ± 0.05| 1.00 ± 0.01 | 1.00 ± 0.05| 1.00 ± 0.08 |

\(^a\) version without metabolic activation; \(^b\) version with metabolic activation.

In the next step, two in vitro cytotoxicity assays were performed using the BALB/c mouse 3T3 fibroblast cell line. The results revealed that in the NRU assay, BALB/c 3T3 cell viability was not decreased by any of the tested samples (Table 3).

Table 3. Results of the NRU test for the highest concentrations of tested extracts (0.5 mg·mL\(^{-1}\)).

| Sample       | Cell Viability ± SD (%) |
|--------------|-------------------------|
| PCL-1        | 96 ± 2                  |
| PCL-2        | 95 ± 1                  |
| Solvent control | 100 ± 5               |

The percentage of viable cells did not differ significantly from the negative control. Moreover, the agar overlay assay also did not reveal any cytotoxic potential of any tested polyesters after 24 h of contact through the agar layer. The results show that there were no changes in the integrity of culture monolayer or general morphology of cells in comparison with the culture control (Figure 2). Moreover, there was no detectable zone around or under the specimen.

![Figure 2](image-url)  
**Figure 2.** Sample PCL-1: (A) no detectable zone around or under specimen; (B) positive control zone with degenerated cells extending up to 0.7 cm around the specimen. Magnification × 200.

3.2. In Vitro Kinetics Release of CIP and TEMP from New Devices

The kinetic release of CIP or TEMP from the selected synthesized matrices (PCL-1-CIT and PCL-1-TEMP, obtained from the PCL-1 matrix; PCL-2-CIT and PCL-2-TEMP, obtained from the PCL-2 matrix) was determined at pH 7.4 and 37 °C over 28 days (Figure 3). The ordinate of the plot was calculated based on the cumulative amount of peptide released [28].
The amount of hydrophobic residue was 61 and 56% for TEMP and CIT, respectively. As a result, TEMP interact stronger with the hydrophobic polymeric matrix. Moreover, a high content of non-polar amino acids in the TEMPs structure (85%) provide to a poor solvation in water as compared to CIT (75% of the non-polar hydrophobic residues).

These differences were probably related to differences in the hydrophobic nature of the peptides. The amount of hydrophobic residue was 61 and 56% for TEMP and CIT, respectively. As a result, TEMP interacted stronger with the hydrophobic polymeric matrix. Moreover, CIT was released more quickly than TEMP. For instance, the amount of peptide released from PCL-1-CIT was about 16.4, 25.4, 39.8, and 52.6% after 7, 14, 21, and 28 days of incubation, respectively, whereas for PCL-1-TEMP these values were about 11.7, 19.4, 29.5, and 40.6% after 7, 14, 21, and 28 days of incubation, respectively. These differences were probably related to differences in the hydrophobic nature of the peptides. The amount of hydrophobic residue was 61 and 56% for TEMP and CIT, respectively. As a result, TEMP interacted stronger with the hydrophobic polymeric matrix. Moreover, a high content of non-polar amino acids in the TEMPs structure (85%) provide to a poor solvation in water as compared to CIT (75% of the non-polar hydrophobic residues).

The release data points were subjected to zero-order and first-order kinetics and the Korsmeyer–Peppas model in order to evaluate the kinetics and mechanisms of peptide release from the obtained polyester matrices (Table 4).

Table 4. Analysis data of peptide release from polymeric matrices.

| No.         | Zero-Order Model | First-Order Model | Korsmeyer–Peppas Model |
|-------------|------------------|-------------------|------------------------|
|             | $R^2$            | $R^2$             | $R^2$                  |
| PCL-1-CIT   | 0.9877           | 0.9574            | 0.9797                 |
| PCL-1-TEMP  | 0.9853           | 0.9603            | 0.9742                 |
| PCL-2-CIT   | 0.9835           | 0.9644            | 0.9732                 |
| PCL-2-TEMP  | 0.9841           | 0.9656            | 0.9722                 |

As is commonly known, according to the Korsmeyer–Peppas model, for the diffusion-degradation–controlled peptide release system, the exponent value ($n$) varies between 0.45 and 0.89 (anomalous, non-Fickian). When $n$ was close to 0.45, diffusion (Fickian diffusion)
dominated in the process. When \( n \) was close to 0.89 (zero-order release), degradation controlled the release [22–24].

Our work shows that the obtained devices demonstrated a rather controlled release profile. High \( R^2 \) values (from 0.9841 to 0.9877) were obtained for the near-zero-order kinetics model. The \( R^2 \) values of the Korsmeyer–Peppas model were also high (from 0.9722 to 0.9797). The controlled drug release profiles were obtained with no significant burst release. This suggests that AMP release from the new PCLs matrices is a highly controlled process. Moreover, Table 4 shows that the exponent \( n \) in the Korsmeyer–Peppas model was approximately above 0.89. This is likely due to a rather degradation-controlled mechanism. The lower peptide release rate from PLA-2 than PLA-1 matrices is a logical consequence of the lower matrices’ crystallinity, because the degradation process is initiated in the amorphous phase [26].

3.3. Analysis of Matrix Surfaces After Degradation

Noncontact laser profilometry and SEM were used to determine the structural changes during the matrix degradation process. Figure 4 presents SEM micrographs and profilometer images of the microstructure of the PCL tablets after 28 days in PBS solution at 37 °C and pH 7.4.

![Figure 4](image-url)

**Figure 4.** SEM micrographs and profilometer images showing the microstructure of PCL tablets after 28 days in PBS solution at 37 °C and pH 7.4: (A) PCL-1-CIT; (B) PCL-1-TEMP; (C) PCL-2-CIT; (D) PCL-2-TEMP.
We could easily see an increase in the depth of holes visible on the tablet surface in the following order: PCL-2-TEMP > PCL-2-CIT > PCL-1-TEMP > PCL-1-CIT. This occurrence confirms our previous assumption that PCL tablets synthesized in [bmim][NTf₂] degraded faster than PCLs synthesized in [bmim][PF₆] due to the lower crystallinity.

Table 5 shows average roughness (Ra) of the tablets and mass loss after incubation in PBS. It was found that the difference in the release rate observed for the PCL devices was also attributed to the difference in Ra values of the PCL matrices. Profilometer analysis indicated that the highest Ra value (5.34) was obtained for PCL-1-CIT. For PCL-1-TEMP and PCL-2-CIT samples, the Ra values were 2.56 and 1.35, respectively. The lowest Ra value was obtained for the PCL-2-TEMP sample (about 0.32). Moreover, percentage mass loss was higher for PCL-1 than PCL-2 devices (54.2–22.8% and 16.4–7.9%, respectively), which is consistent with our previous report [20].

As it is commonly known, PCL is water-insoluble polymer. However, it is hydrolytically unstable and is degraded by hydrolysis of ester bonds. The process first occurs in the amorphous regions and is followed by a slower degradation in crystalline regions. Various studies have revealed that PCLs degradation is a result of several simultaneously occurring processes. These include water uptake, swelling, ester hydrolysis, diffusion of oligomers and degradation products, and local pH drop [29,30]. However, completely explanation of the mechanism which involves several factors is not yet possible.

### 3.4. Evaluation of Therapeutic Effect of New AMP Devices

From the therapeutic point of view, it is very important to achieve therapeutic concentration of APIs in the target tissue. In the current work, we also investigated the daily release rate of AMPs after 1, 7, 14, 21, and 28 days (Figure 5) considering their reported MIC and MHC values [13,31]. We focused on the anti-infectious effect of AMPs in infections caused by major pathogens in surgical wound infections, *Staphylococcus aureus, Enterococcus faecalis, Escheria coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa* [32].

CIT, due to its higher TI value (8.8), shows greater antimicrobial specificity as compared to TEMP (TI = 4.5). This indicates that CIT could be a promising antimicrobial compound for polymeric devices in wound infections. However, regardless the type of API, the type of matrix is a key factor for effective therapy. It was noted that PCL-2 was the best matrix for CIT. New PCL-2-CIT devices reach therapeutic concentration of AMPs (about 110–190 µg·mL⁻¹) within 24 h and maintain it for the next 28 days. For TEMP, the most effective matrix appeared to be PCL-1, with peptide daily release of about 130–190 µg·mL⁻¹ for 28 days.

For PCL-1, the peptide maximum daily concentration was dependent on the type of APIs. In the case of TEMP, maximum concentration was reached after 14 days of incubation in PBS at pH 7.4 at 37 °C. Interestingly, the maximum CIT daily release concentration was reached after 7 and 21 days (about 280 µg·mL⁻¹), and this value exceeded the MHC values (about 256 µg·mL⁻¹ [31]). For PCL-2, the highest daily concentration of both peptides was noted after 21 days.

Table 5. Parameters of surface roughness and mass loss after 28 days in PBS solution at 37 °C and pH 7.4.

| No.          | Ra ± SD | Mass Loss ± SD (%) |
|--------------|---------|-------------------|
| PCL-1-CIT    | 5.34 ± 1.60 | 54.2 ± 2.2        |
| PCL-1-TEMP   | 2.56 ± 0.74 | 22.8 ± 1.7        |
| PCL-2-CIT    | 1.35 ± 0.75 | 16.4 ± 0.9        |
| PCL-2-TEMP   | 0.32 ± 0.10 | 7.9 ± 0.5         |
Figure 5. Peptide daily concentration after 1, 7, 14, 21, and 28 days of incubation in PBS solution at 37 °C and pH 7.4: (A) CIT; (B) TEMP. Geometric values of minimal inhibitory concentration (MIC) and minimal hemolytic concentration (MHC) were taken from the literature [13,31].

4. Conclusions

In the present work, new nontoxic polymeric matrices for controlled CIT and TEMP release were obtained. PCLs with different crystallinity were successfully synthesized by eROP in two different ILs, [bmim][NTf₂] and [bmim][PF₆]. The in vitro release study demonstrated that CIT and TEMP release rates were strongly dependent on the crystallinity of the polymeric matrices. However, peptide characteristics were also important. CIT, a less hydrophobic peptide, was released more quickly than the more hydrophobic TEMP. We found that the peptides were released with high control, according to the degradation mechanism with near-zero-order kinetics. The peptide “burst release” was not observed during the degradation process. New devices reached a therapeutic concentration of AMPs within 24 h and maintained it for 28 days. From a broader perspective, this study suggests that synthesized polyester matrices may contribute to a potential application as medium- and long-term controlled CIT or TEMP delivery systems, offering fast antibacterial effects on local infections in implantology.

Author Contributions: U.P. conceived, designed, and directed the studies, performed the synthesis and physicochemical characterization of the materials and new devices, and wrote the manuscript. M.S., E.O., and M.B. performed the peptide release studies (tests and their interpretation) and helped write the paper. A.Z. performed geno- and cytotoxicity assays (tests and their interpretation). All authors read and approved the final manuscript.
Acknowledgments: This work was financially supported by the National Science Centre (Poland), PRELUDIUM 6 research scheme, decision No. DEC-2013/11/N/NZ7/02342 (“Synthesis, physico-chemical and biological studies on macromolecular carriers of antimicrobial peptides”) and funded with the assistance of the Ministry of Science and Higher Education from subsidies for statutory activity, project No. 3086/35/P (“Development of formulations and technologies for the manufacture of innovate cosmetics, pharmacy supplies, household and industrial chemicals”). The authors are indebted to Violetta Kowalska from the Medical University of Warsaw and Dominik Czerwonka from the Kazimierz Pulaski University of Technology and Humanities in Radom for the performance of the NMR (V.K.) and roughness (D.C.) measurements.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Gomes, B.; Augusto, M.T.; Felicio, M.R.; Hollmann, A.; Franco, O.L.; Gonçalves, S.; Santos, N.C. Designing improved active peptides for therapeutic approaches against infectious diseases. Biotechnol. Adv. 2018, 36, 415–429. [CrossRef] [PubMed]

2. Coates, A.R.; Halls, G.; Hu, Y. Novel classes of antibiotics or more of the same? Br. J. Pharmacol. 2011, 163, 184–194. [CrossRef] [PubMed]

3. Hu, Y.; Shamaei-Tousi, A.; Liu, Y.; Coates, A. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: A novel topical antibiotic for staphylococcal infections. PLoS ONE 2010, 5, e11818. [CrossRef] [PubMed]

4. Jenssen, H.; Hamill, P.; Hancock, R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19, 491–511. [PubMed]

5. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389–395. [CrossRef]

6. Piotrowska, U.; Sobczak, M.; Oledzka, E. Current state of a dual behaviour of antimicrobial peptides—Therapeutic agents and promising delivery vectors. Chem. Biol. Drug Des. 2017, 90, 1079–1093. [CrossRef] [PubMed]

7. Zhao, Y.N.; Xu, X.; Wen, N.; Song, R.; Meng, Q.; Guan, Y.; Cheng, S.; Cao, D.; Dong, Y.; Qie, J.; et al. A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics. Sci. Rep. 2017, 7, 5524. [CrossRef] [PubMed]

8. Eckhard, L.H.; Sol, A.; Abtew, E.; Shai, Y.; Domb, A.J.; Bachrach, G.; Beyth, N. Biohybrid polymer-antimicrobial peptide medium against Enterococcus faecalis. PLoS ONE 2014, 9, e109413. [CrossRef] [PubMed]

9. Sobczak, M.; Kamysz, W.; Tyszkieiwicz, W.; Dębek, C.; Kozłowski, R.; Oledzka, E.; Piotrowska, U.; Nałęcz-Jawecki, G.; Plichta, A.; Grzywacz, D. Biodegradable macromolecular conjugates of citropin: Synthesis, characterization and in vitro efficiency study. React. Funct. Polym. 2014, 83, 54–61. [CrossRef]

10. Pranantyo, D.; Xu, L.Q.; Kang, E.-T.; Mya, M.K.; Chan-Park, M.B. Conjugation of Polyphosphoester and Antimicrobial Peptide for Enhanced Bactericidal Activity and Biocompatibility. Biomacromolecules 2016, 17, 4037–4044. [CrossRef] [PubMed]

11. Chen, Y.; Mant, C.T.; Farmer, S.W.; Hancock, R.E.; Vasil, M.L.; Hodges, R.S. Rational design of α-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J. Biol. Chem. 2005, 280, 12316–12329. [CrossRef] [PubMed]

12. Sikorska, E.; Greber, K.; Rodziewicz-Motowidlo, S.; Szultzka, L.; Łukasiak, J.; Kamysz, W. Synthesis and antimicrobial activity of truncated fragments and analogs of citropin 1.1: The solution structure of the SDS micelle-bound citropin-like peptides. J. Struct. Biol. 2009, 168, 250–258. [CrossRef] [PubMed]

13. Giacometti, A.; Cirioni, O.; Kamysz, W.; Silvestri, C.; Del Prete, M.S.; Licci, A.; Damato, G.; Łukasiak, J.; Scalise, G. In vitro activity and killing effect of citropin 1.1 against Gram-positive pathogens causing skin and soft tissue infections. Antimicrob. Agents Chemother. 2005, 49, 2507–2509. [CrossRef] [PubMed]

14. Giacometti, A.; Cirioni, O.; Kamysz, W.; Silvestri, C.; Del Prete, M.S.; Licci, A.; Damato, G.; Łukasiak, J.; Scalise, G. In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. Antimicrob. Agents Chemother. 2005, 56, 410–412. [CrossRef] [PubMed]

15. Doyle, J.; Brinkworth, C.S.; Wegener, K.L.; Carver, J.A.; Llewellyn, L.E.; Olver, I.N.; Bowie, J.H.; Wabnitz, P.A.; Tyler, M.J. nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications. Eur. J. Biochem. 2003, 270, 1141–1153. [CrossRef] [PubMed]
16. Mulder, K.C.; Lima, L.A.; Miranda, V.J.; Dias, S.C.; Franco, O.L. Current scenario of peptide-based drugs: The key roles of cationic antitumor and antiviral peptides. *Front. Microbiol.* **2013**, *4*, 1–23. [CrossRef] [PubMed]

17. Wade, D.; Silberring, J.; Soliymani, R.; Heikkinen, S.; Kilpeläinen, I.; Lankinen, H.; Kuusela, P. Antibacterial activities of temporin A analogs. *FEBS Lett.* **2000**, *479*, 6–9. [CrossRef]

18. Vekariya, R.L. A review of ionic liquids: Applications towards catalytic organic transformations. *J. Mol. Liq.* **2016**, *227*, 44–60. [CrossRef]

19. Piotrowska, U.; Sobczak, M.; Oledzka, E. Characterization of aliphatic polyesters synthesized via enzymatic ring-opening polymerization in ionic liquids. *Molecules* **2017**, *22*, 923. [CrossRef] [PubMed]

20. Piotrowska, U.; Sobczak, M.; Oledzka, E.; Combes, C. Effect of ionic liquids on the structural, thermal, and in vitro degradation properties of poly(epsilon-caprolactone) synthesized in the presence of *Candida antarctica* lipase B. *J. Appl. Polym. Sci.* **2016**, *133*, 10. [CrossRef]

21. Zółtowska, K.; Piotrowska, U.; Oledzka, E.; Kuras, M.; Zgadzaj, A.; Sobczak, M. Biodegradable Poly (ester-urethane) Carriers Exhibiting Controlled Release of Epirubicin. *Pharm. Res.* **2017**, *34*, 780–792. [CrossRef] [PubMed]

22. Alexis, F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. *Polym. Int.* **2005**, *54*, 36–46. [CrossRef]

23. Siepmann, J.; Göpferich, A. Mathematical modeling of bioerodible, polymeric drug delivery systems. *Adv. Drug Deliv. Rev.* **2001**, *48*, 229–247. [CrossRef]

24. Dash, S.; Murthy, P.N.; Nath, L.; Chowdhury, P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol. Pharm.* **2010**, *67*, 217–223. [PubMed]

25. Kobayashi, S. Lipase-catalyzed polyester synthesis—A green polymer chemistry. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* **2010**, *86*, 338–365. [CrossRef] [PubMed]

26. Bosworth, L.A.; Downes, S. Physicochemical characterisation of degrading polycaprolactone scaffolds. *Polym. Degrad. Stab.* **2010**, *95*, 2269–2276. [CrossRef]

27. Woodruff, M.A.; Hutmacher, D.W. The return of a forgotten polymer—Polycaprolactone in the 21st century. *Prog. Polym. Sci.* **2010**, *35*, 1217–1256. [CrossRef]

28. Zółtowska, K.; Piotrowska, U.; Oledzka, E.; Luchowska, U.; Sobczak, M.; Bocho-Janiszewska, A. Development of biodegradable polyesters with various microstructures for highly controlled release of epirubicin and cyclophosphamide. *Eur. J. Pharm. Sci.* **2017**, *96*, 440–448. [CrossRef] [PubMed]

29. Göpferich, A. Mechanism of polymer degradation and erosion. *Biomaterials* **1996**, *17*, 103–114. [CrossRef]

30. Avgoustakis, K.; Nixon, J.R. Biodegradable controlled tablets 3. Effect of polymer characteristics on drug release. *Int. J. Pharm.* **1993**, *99*, 247–252. [CrossRef]

31. Neubauer, D.; Jaśkiewicz, M.; Migoń, D.; Bauer, M.; Sikora, K.; Sikorska, E.; Kamysz, E.; Kamysz, W. Retro analog concept: Comparative study on physico-chemical and biological properties of selected antimicrobial peptides. *Amino Acids* **2017**, *49*, 1755–1771. [CrossRef] [PubMed]

32. Giacometti, A.; Cirioni, O.; Schimizzi, A.M.; Del Prete, M.S.; Barchiesi, F.; D’errico, M.M.; Petrelli, E.; Scalise, G. Epidemiology and microbiology of surgical wound infections. *J. Clin. Microbiol.* **2000**, *38*, 918–922. [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).